Evidence map›Paper›PMID 33919694›Full record

ReviewMolecules (Basel, Switzerland)2021

Insights into Multifunctional Nanoparticle-Based Drug Delivery Systems for Glioblastoma Treatment.

Mohd Khan, Subuhi Sherwani, Saif Khan, Sultan Alouffi, Mohammad Alam, Khalid Al-Motair, Shahper Khan

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Mohd KhanDepartment of Chemistry, College of Sciences, University of Ha'il, Ha'il 2440, Saudi Arabia.
Subuhi SherwaniDepartment of Biology, College of Sciences, University of Ha'il, Ha'il 2440, Saudi Arabia.
Saif KhanDepartment of Basic Dental and Medical Sciences, College of Dentistry, University of Ha'il, Ha'il 2440, Saudi Arabia.
Sultan AlouffiMolecular Diagnostic and Personalised Therapeutics Unit, University of Ha'il, Ha'il 2440, Saudi Arabia.ORCID 0000-0003-3443-9700
Mohammad AlamDepartment of Biology, College of Sciences, University of Ha'il, Ha'il 2440, Saudi Arabia.ORCID 0000-0003-0144-6517
Khalid Al-MotairMolecular Diagnostic and Personalised Therapeutics Unit, University of Ha'il, Ha'il 2440, Saudi Arabia.
Shahper KhanInterdisciplinary Nanotechnology Centre, Aligarh Muslim University, Aligarh 202002, U.P., India.
University of Ha'il · SAAligarh Muslim University · IN

Funding

The authors extend their appreciation to the Deputy for research & Innovation, Ministry of Education in Saudi Arabia for funding this research work through the project number RDO-2002. RDO-2002
6 · The paper itself

Abstract

Glioblastoma (GB) is an aggressive cancer with high microvascular proliferation, resulting in accelerated invasion and diffused infiltration into the surrounding brain tissues with very low survival rates. Treatment options are often multimodal, such as surgical resection with concurrent radiotherapy and chemotherapy. The development of resistance of tumor cells to radiation in the areas of hypoxia decreases the efficiency of such treatments. Additionally, the difficulty of ensuring drugs effectively cross the natural blood-brain barrier (BBB) substantially reduces treatment efficiency. These conditions concomitantly limit the efficacy of standard chemotherapeutic agents available for GB. Indeed, there is an urgent need of a multifunctional drug vehicle system that has potential to transport anticancer drugs efficiently to the target and can successfully cross the BBB. In this review, we summarize some nanoparticle (NP)-based therapeutics attached to GB cells with antigens and membrane receptors for site-directed drug targeting. Such multicore drug delivery systems are potentially biodegradable, site-directed, nontoxic to normal cells and offer long-lasting therapeutic effects against brain cancer. These models could have better therapeutic potential for GB as well as efficient drug delivery reaching the tumor milieu. The goal of this article is to provide key considerations and a better understanding of the development of nanotherapeutics with good targetability and better tolerability in the fight against GB.

Indexed as

Drug Delivery SystemsAnimalsBrain NeoplasmsCell MembraneGlioblastomaHumansMultifunctional NanoparticlesNanotechnologyblood–brain barrierglioblastomamulticoremultifunctionalnanotherapeuticpolymeric nanoparticles

Identifiers

PMID33919694
PMCPMC8069805
OpenAlexW3155952860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.